New drug combo may shrink bleeding plaques in neck arteries, cutting stroke risk

NCT ID NCT07586540

Not yet recruiting Disease control Sponsor: Middle East North Africa Stroke and Interventional Neurotherapies Organization Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding alirocumab (a cholesterol-lowering injection) to standard statin therapy can reduce bleeding inside fatty plaques in the carotid artery. About 280 people with a recent mini-stroke or stroke due to a 50-69% blocked neck artery will receive either alirocumab or a placebo every two weeks for 26 weeks, with MRI scans to measure plaque changes. The goal is to see if the drug makes plaques less dangerous and lowers the chance of future strokes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CAROTID STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carotid stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CAROTID STENOSIS

Contacts and locations

Locations

Aga Khan University

Karachi, Pakistan
Ain Shams University

Cairo, Egypt
Alexandria University, Smouha University Comprehensive Stroke Center

Alexandria, Egypt
Amman Specialized IR Center

Amman, Jordan
Cairo University

Cairo, Egypt
Centre Hospitalier Universitaire Ibn Sina de Rabat

Rabat, Morocco
Department of Neurology, Eskisehir Osmangazi University

Eskişehir, Turkey (Türkiye)
Institut National de Neurologie

Tunis, Tunisia
King Abdulaziz Medical City

Jeddah, Saudi Arabia
King Abdullah Medical City

Mecca, Saudi Arabia
King Khalid University

Abhā, Saudi Arabia
Neurology Department, Al-Azhar University

Cairo, Egypt
Neurology Department, Dr. Lutfi Kirdar City Hospital

Istanbul, Turkey (Türkiye)
Weill Cornell Medicine-Qatar

Doha, Qatar

More trials for these conditions

Other studies related to the condition(s) this trial covers.